Physician profile
Alexandra Stefanovic
NPI 1033310701
$4,386.54
in general payments reported to CMS, 2019-2025
12 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $85.00 · 2021: $2,188 · 2023: $138 · 2024: $697 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,625 · Food and Beverage: $434 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,625.00 |
| Food and Beverage | $433.60 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $1,980.00 | 2021 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $525.00 | 2024 | Calquence |
| Sobi, INC | $287.87 | 2023-2024 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Recordati_rare_diseases_inc. | $125.99 | 2025 | Sylvant |
| Novartis Pharmaceuticals Corporation | $125.00 | 2021 | |
| Genentech USA, INC. | $85.00 | 2020 | |
| Epizyme, INC. | $82.95 | 2021 | |
| Celgene Corporation | $52.95 | 2025 | Breyanzi |
| Motiva USA, LLC | $21.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Stefanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.